Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112

8100 Background: Based on limited data, NSCLC guidelines from ASCO includes non-platinum (non-P) therapy. D0112 provided the highest evidence supporting this guideline. Survival for this non-P and a carboplatin combination were equivalent. Recently, treatment choices and duration are based on subgroups of NSCLC. This report addresses the outcomes for subgroups from this trial. Methods: Eligibility patients (pts) with IIIB/IV NSCLC, performance status (PS) 0–2, and no prior chemotherapy. Randomized pts were stratified by stage (IIIB vs IV) and PS (0–1 vs 2) to arm A: carboplatin + docetaxel or arm B: gemcitabine + docetaxel. Therapy duration following 6 cycles was at the discretion of the investigator. Gender, histology, stage, PS, prior radiation, and central nervous system (CNS) metastasis were identified as independent variables. Multivariable analysis was performed using a proportional hazards regression. Wald test was performed. Treatment effect for each subgroups was evaluated. Results: Median follow...